In Sep 2017, Huarui SmartLink completed an investment in Yangtze River Delta, China Pharmaceutical Distribution Consolidation Platform through an Industrial Acquisition transaction, with committed capital of CNY 1.8B. The asset is currently valued at CNY 4.6B (2025 Valuation), and has become one of the firm's key tracked opportunities within its global multi-asset allocation framework.

Channel reform, pharma distribution consolidation, and supply-chain upgrades improved scale economics and margins for regional healthcare logistics leaders. Based on its assessment of industry trends, valuation levels, and market liquidity, the team continues to deepen research coverage and post-investment monitoring around this opportunity.

The investment achieved its main exit in 2023 through industry consolidation, with only a small residual earn-out-related interest remaining in 2025. In parallel, the investment also improves medicine distribution efficiency, cold-chain compliance, and healthcare access in lower-tier markets. This remains consistent with Huarui SmartLink's investment approach centered on long-term thinking, balanced risk-adjusted returns, and sustainable value creation.